Annals of Surgical Treatment and Research

The Korean Surgical Society (대한외과학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Combination of Anticancer Agents and Nitroimidazoles on the Survival of Human Hepatocellular Carcinoma Cells under Hypoxic Conditions

저산소 조건에서 항암제와 니트로이미다졸 복합제제가 인간 간암 세포의 생존에 미치는 영향

Lim, Sun-Ha;Lee, June-Yeob;Park, Sung-Hwan;Kim, You-Hee;Suh, Hun-Suk;Park, Jae-Bok;Lee, Jong-Won
임선하;이준엽;박성환;김여회;서헌석;박재복;이종원

  • Published : 20090600
⟨ Previous Next ⟩

Abstract

Purpose: In a previous study, we have shown that anticancer agents inhibiting topoisomerases improve survival of tumor cells under hypoxic condition. In the present study, we evaluated whether and how cell survival effect of the anticancer agents under hypoxic conditions could be eliminated by the addition of nitroimidazoles, a class of bioreductive agents. Methods: Human hepatocellular carcinoma cells (HepG2) were incubated with different combinations of pimonidazole (1${\sim} 1,000 {\mu}g$/ml) and doxorubicin (0.1 or 1${\mu}g$/ml) concentrations under different $O_2$ concentrations [1, 3, 5, 10 and 21 $O_2$]. Then cell numbers, glucose concentrations and lactic acid concentrations in the medium were measured, and DNA fragmentation assay was performed. Finally, different combinations of nitroimidazoles, such as pimonidazole, misonidazole, etanidazole, tinidazole, metronidazole, ornidazole or dimetridazole, and anticancer agents, such as doxorubicin, campothecin, epirubicin, dactinomycin, etoposide or mitomycin C was added to the cell culture medium under hypoxic conditions (1% $O_2$). Results: Pimonidazole at a concentration of 100${\mu}g$/ml eliminated cell survival effect of doxorubicin at the concentrations of 0.1 and 1${\mu}g$/ml under hypoxic condition (1% $O_2$) by promoting apoptosis. Almost all the cells died even after 24 hours of incubation for all the oxygen concentrations at a combination of 100${\mu}g$/ml pimonidazole and 1${\mu}g$/ml doxorubicin. Finally, pimonidazole at a concentration of 100${\mu}g$/ml, and misonidazole or etanidazole at a concentration of 1,000${\mu}g$/ml eliminated cell survival effect of all the anticancer agents tested under hypoxic condition. Conclusion: Combination therapy of doxorubicin (adriamycin) with pimonidazole can maximize dororubicin efficacy by eliminating cell survival effect of doxorubicin under hypoxic conditions in treating solid tumors, such as breast cancer.

Keywords

References

  1. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007;85:1301-7 https://doi.org/10.1007/s00109-007-0281-3
  2. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(Suppl 5):4-9
  3. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 2007;12:690-712 https://doi.org/10.1634/theoncologist.12-6-690
  4. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue:a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84
  5. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39 https://doi.org/10.1007/s10555-007-9055-1
  6. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia:a target for selective cancer therapy. Cancer Sci 2003;94:1021-8 https://doi.org/10.1111/j.1349-7006.2003.tb01395.x
  7. Kurebayashi J, Otsuki T, Moriya T, Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 2001;92:1093-101 https://doi.org/10.1111/j.1349-7006.2001.tb01064.x
  8. Lee YT, Han MJ, Lim SH, Park SH, Suh HS, Park JB, et al. Effect of antibiotics on the survival of human hepatocellular carcinoma cells under hypoxic conditions. J Korean Surg Soc 2006;71:31-8
  9. Kim HS, Lee YM, Yoo MA, Lee JW, Ryu SH, Kim KW. Ofloxacin inhibits hypoxia/hypoglycemia-induced apoptosis in bovine aortic endothelial cells. J Korean Assoc Cancer Prev 2001;6:155-64
  10. Lee JY, Lim SH, Park SH, Ahn KS, Suh HS, Lee J. Effect of antitumor agents on the survival of human hepatocellular carcinoma cells under hypoxic conditions. Korean J Med 2007;72:384-92
  11. Denny WA. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol 2000;1:25-9 https://doi.org/10.1016/S1470-2045(00)00006-1
  12. Tocher JH. Reductive activation of nitroheterocyclic compounds. Gen Pharmacol 1997;28:485-7 https://doi.org/10.1016/S0306-3623(96)00283-2
  13. Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990;50:3339-44
  14. Brenner DE, Galloway S, Cooper J, Noone R, Hande KR. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography. Cancer Chemother Pharmacol 1985;14:139-45 https://doi.org/10.1007/BF00434353
  15. Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, et al. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993;32:379-84 https://doi.org/10.1007/BF00735923
  16. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:397-417 https://doi.org/10.1016/j.clon.2007.03.010
  17. Roberts JT, Bleehen NM, Workman P, Walton MI. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799. Int J Radiat Oncol Biol Phys 1984;10:1755-8 https://doi.org/10.1016/0360-3016(84)90543-1
  18. Saunders MI, Anderson PJ, Bennett MH, Dische S, Minchinton A, Stratford MR, et al. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations. Int J Radiat Oncol Biol Phys 1984;10:1759-63 https://doi.org/10.1016/0360-3016(84)90544-3
  19. A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 1993;26:93-103 https://doi.org/10.1016/0167-8140(93)90089-Q
  20. Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J, et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix:final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1999;44:513-7 https://doi.org/10.1016/S0360-3016(99)00054-1
  21. Chan P, Milosevic M, Fyles A, Carson J, Pintilie M, Rauth M, et al. A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 2004;70:295-9 https://doi.org/10.1016/j.radonc.2003.11.018
  22. Drzymala RE, Wasserman TH, Won M, Shaw E, Cmelak AJ, Loeffler J, et al. A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02). Radiother Oncol 2008;87:89-92 https://doi.org/10.1016/j.radonc.2008.02.006
  23. Urtasun R, Feldstein ML, Partington J, Tanasichuk H, Miller JD, Russell DB, et al. Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial. Br J Cancer 1982;46:101-8 https://doi.org/10.1038/bjc.1982.171
  24. Brezden CB, McClelland RA, Rauth AM. Mechanism of the selective hypoxic cytotoxicity of 1-methyl-2-nitroimidazole. Biochem Pharmacol 1994;48:361-70 https://doi.org/10.1016/0006-2952(94)90108-2
  25. Kuno Y, Shinomiya N. PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction. Apoptosis 2000;5:69-77 https://doi.org/10.1023/A:1009641827022
  26. Thomas CL. Taber's Cyclopedic Medical Dictionary. 17th ed. Philadelphia: F.A. Davis; 1993
  27. Newman HF, Ward R, Workman P, Bleehen NM. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1988;15:1073-83 https://doi.org/10.1016/0360-3016(88)90187-3
  28. Bleehen NM, Newman HF, Maughan TS, Workman P. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1989;16:1093-6 https://doi.org/10.1016/0360-3016(89)90924-3

Cited by

  1. Methanol Extract of Cassia mimosoides var. nomame and Its Ethyl Acetate Fraction Attenuate Brain Damage by Inhibition of Apoptosis in a Rat Model of Ischemia-Reperfusion vol.15, pp.4, 2009, https://doi.org/10.3746/jfn.2010.15.4.255
  2. Attenuation of Brain Injury by Water Extract of Goat's-beard (Aruncus dioicus) and Its Ethyl Acetate Fraction in a Rat Model of Ischemia-Reperfusion vol.16, pp.3, 2011, https://doi.org/10.3746/jfn.2011.16.3.217
  3. Identification of active compounds from Aurantii Immatri Pericarpium attenuating brain injury in a rat model of ischemia-reperfusion vol.138, pp.1, 2009, https://doi.org/10.1016/j.foodchem.2012.09.137